H-GVGSPYVSRLLGICL-OH

Ref. 3D-PP43975

Informação sobre produto

• Nome: H-GVGSPYVSRLLGICL-OH
• Sinónimos: NH2-Gly-Val-Gly-Ser-Pro-Tyr-Val-Ser-Arg-Leu-Leu-Gly-Ile-Cys-Leu-OH

Descrição

Peptide H-GVGSPYVSRLLGICL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-GVGSPYVSRLLGICL-OH include the following: Application of HER2 peptide vaccines in patients with breast cancer: a systematic review and meta-analysis Z You, W Zhou, J Weng, H Feng, P Liang, Y Li - Cancer Cell , 2021 - Springerhttps://link.springer.com/article/10.1186/s12935-021-02187-1 From bench to bedside: The use of the li-Key technology to improve helper peptides for clinical use in cancer vaccines. TJ Vreeland , DF Hale, AK Sears, GT Clifton, E Pappou - 2012 - ascopubs.orghttps://ascopubs.org/doi/abs/10.1200/jco.2012.30.15_suppl.2508 Invariant chain-peptide fusion vaccine using HER-2/neu SA Perez , GE Peoples, M Papamichail - Vaccines: Methods and , 2014 - Springerhttps://link.springer.com/protocol/10.1007/978-1-4939-0345-0_26 AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial SA Perez , EA Anastasopoulou, P Tzonis - Cancer Immunology , 2013 - Springerhttps://link.springer.com/article/10.1007/s00262-013-1461-3 Improving potency of Nanoliposomal AE36 peptide vaccine by adding CD4+ T cell helper epitope and MPL in TUBO breast cancer mice model P Zamani, M Mashreghi , MR Bazaz , F Mirzavi - Journal of Drug Delivery , 2022 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1773224722002568 Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100 (48-58) MHC NL Kallinteris, S Wu , X Lu, RE Humphreys - Journal of , 2005 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2005/07000/Enhanced_CD4__T_Cell_Response_in_DR4_Transgenic.00010.aspx Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer M Harao, EA Mittendorf, LG Radvanyi - BioDrugs, 2015 - Springerhttps://link.springer.com/article/10.1007/s40259-014-0114-1 Circulating regulatory T cells (CD4+ CD25+ FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide JD Gates, GT Clifton, LC Benavides, AK Sears - Vaccine, 2010 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X10013393 Early results of a phase I clinical trial of an Ii-Key/Her2/neu MHC class II peptide-based vaccine in breast cancer patients EA Mittendorf, S Khoo, CE Storrer, KA Harris - Journal of Clinical , 2006 - ascopubs.orghttps://ascopubs.org/doi/abs/10.1200/jco.2006.24.18_suppl.2532 The Fourteenth International Conference on Progress in Vaccination Against Cancer (PIVAC-14), September 24-26, 2014, Rome, Italy: Rethinking anti-tumor E Signori, F Cavallo - 2015 - Springerhttps://link.springer.com/article/10.1007/s00262-015-1676-6 Whole tumor antigen vaccines CLL Chiang , F Benencia, G Coukos - Seminars in immunology, 2010 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1044532310000205

• Marca: Biosynth